Flt3 receptor antagonists for the treatment or the prevention of pain disorders
AssigneesInstitut National De La Sante Et De La Recherche Medicale (Inserm), Universite De Montpellier 1, Universite Montpellier 2 Sceinces Et Techniques
InventorJean VALMIER
Life of this patent
Estimating the term…
Abstract
The present invention relates to FLT3 receptor antagonists or inhibitors of FLT3 receptor gene expression for the treatment or the prevention of pain disorders.
Claims18
1-10. (canceled)
A pharmaceutical composition for the treatment or the prevention of pain which comprises a FLT3 receptor antagonist.
A method for screening an FLT3 receptor antagonist for the treatment or the prevention of pain disorders comprising the steps consisting of:
- a) providing a plurality of cells expressing FLT3 on their surface;
- b) incubating said cells with a candidate compound;
- c) determining whether said candidate compound binds to and inhibits FLT3;
- and
- d) selecting the candidate compound that binds to and inhibits FLT3.
A method for screening an FLT3 receptor antagonist for the treatment or the prevention of pain disorders comprising the steps consisting of:
- a) determining the ability of a candidate compound to inhibit the interaction between a FLT3 polypeptide and a FL polypeptide, and
- b) selecting positively the candidate compound that inhibits said interaction.
A method of treating or preventing pain disorders in a patient in need thereof, comprising the step of
- administering to said patient a therapeutic amount of an FLT3 receptor antagonist.
A method of treating or preventing pain disorders in a patient in need thereof, comprising the step of
- administering to said patient a therapeutically effective amount of an inhibitor of FLT3 receptor gene expression.
A pharmaceutical composition for the treatment or the prevention of pain which comprises
- an inhibitor of FLT3 receptor gene expression.
Dependencies are inferred from the claim text.